Fasikl

Executive Summary

Fasikl is a neurotechnology and AI therapeutics company headquartered in Cambridge, MA, founded in 2021. The company has developed an integrated cloud-based AI platform that decodes and modulates neural signals to treat neurological and movement disorders. Its first commercial product, the Felix NeuroAI™ Wristband, is an FDA-cleared, non-invasive therapeutic device for essential tremor. By leveraging real-time neural signal processing, the device offers a novel alternative to medications or invasive procedures, potentially improving patient compliance and quality of life. Fasikl's AI-driven approach differentiates it in the neurostimulation market, which is dominated by invasive deep brain stimulation and pharmaceuticals with side effects. As a private company with a commercialized product, Fasikl is positioned for growth in the neurological device space. The essential tremor market alone represents a significant opportunity, with millions of patients seeking non-pharmacological options. The company's platform technology can be extended to other movement disorders such as Parkinson's disease, creating a pipeline of indications. Near-term success depends on commercialization execution, securing reimbursement, and expanding clinical evidence. If Fasikl can demonstrate real-world efficacy and build strategic partnerships, it has the potential to become a leader in non-invasive neuromodulation. However, as a young company, it faces risks including market adoption, competition from established players, and the need for additional funding to scale operations. Overall, Fasikl represents a promising investment opportunity in the convergence of AI and neurotechnology.

Upcoming Catalysts (preview)

• Q2 2027Initiation of pivotal trial for Parkinson's tremor indication40% success
• Q3 2026Commercial partnership with large healthcare provider or distributor60% success
• Q4 2026Series A funding round to scale commercialization70% success